Abstract
Linezolid is the first of a new class of antimicrobial agents, the oxazolidinones, with a high degree of in vitro activity against a variety of gram-positive pathogens, notably, Staphylococcus aureus (both methicillin-susceptible and -resistant), enterococci (both vancomycin-susceptible and -resistant), and pneumococci (both penicillin-susceptible and -resistant). The MICs for these organisms are usually ≤4 μg/ml, which is considered susceptible. Linezolid is indicated for the therapy of pneumonia, skin and soft tissue infections, and bacteremia caused by these pathogens. Laboratory testing and reporting of this agent against methicillin-resistant S. aureus, vancomycin-resistant enterococci, and penicillin-resistant pneumococci are indicated when they are encountered. The drug has good bioavailability with limited side effects and can be administered orally or intravenously.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
